HCV SERVICE INNOVATIONS IN DRUG TREATMENT PROGRAMS

描述：(申请人摘要) 丙型肝炎是目前最常见的威胁生命的疾病 在注射吸毒者中，慢性丙型肝炎病毒感染的并发症有 在接下来的几年里，这一人口可能会急剧增加。 药物治疗计划的独特之处在于提供关键的丙型肝炎病毒服务 对注射吸毒者和非注射吸毒者都适用。然而，目前有 几乎没有关于药物治疗领域反应的系统信息 丙型肝炎病毒的流行。因此，研究的主要目的是：(1) 衡量三种类型的丙型肝炎病毒服务(教育和 咨询、抗体检测、医疗管理和监测) 由全国范围内的药物治疗计划样本(N=800)提供，并比较 跨药物治疗方式的丙型肝炎病毒相关服务水平；(2)模型 这些药物治疗计划提供的丙型肝炎服务水平 根据客户特点、组织结构和资源， 与方案环境中的公共卫生组织的关系， 为医疗服务提供内部支持，并提供其他医疗服务 服务(特别是艾滋病毒和甲型和乙型肝炎服务)；(3)办案 研究(N=24)药物治疗方案，以了解创新 进程(即丙型肝炎病毒服务的采用和发展)和当前 实施过程(丙型肝炎病毒服务提供做法和程序)；和(4) 了解客户对丙型肝炎病毒服务和服务交付的看法 案例研究现场的流程，以及他们的看法是否一致 和工作人员的一样。研究将对定量调查数据进行分析，以 评估丙型肝炎病毒服务的结构，并评估定性的案例研究数据 创新和实施过程。研究成果的传播 药物治疗领域的发现有望提高人们对 需要适当地应对丙型肝炎疫情，协助丙型肝炎病毒的倡导者 服务促进服务的发展，并协助计划 希望通过向他们告知“最佳实践”来增强服务。

DESCRIPTION: (Applicant's Abstract) Hepatitis C (HCV) is currently the most prevalent life threatening disease among injection drug users, and complications from chronic HCV infection are likely to increase dramatically in this population in the next several years. Drug treatment programs are uniquely situated to provide critical HCV services to both IDUs and non-injecting drug users. Currently, however, there is virtually no systematic information about the drug treatment field's response to the HCV epidemic. The main purposes of the research are, therefore, to: (1) measure the extent to which three types of HCV services (education and counseling, antibody testing, and medical management and monitoring) are provided by a nationwide sample (N=800) of drug treatment programs, and compare the level of HCV related services across drug treatment modalities; (2) model the level of HCV services that these drug treatment programs provide on the basis of client characteristics, organizational structure and resources, relationships with public health organizations in the programs' environment, internal support for medical services, and the provision of other medical services (especially services for HIV and hepatitis A and B); (3) conduct case studies (N=24) of drug treatment programs in order to understand the innovation process (i.e., the adoption and development of HCV services) and the current implementation process (HCV service delivery practices and procedures); and (4) understand clients' perceptions of HCV services and the service delivery process in the case study sites, and whether their perceptions are congruent with those of staff. The research will analyze quantitative survey data to assess the structure of HCV services, and qualitative case study data to assess the innovation and implementation processes. The dissemination of research findings to the drug treatment field is expected to elevate consciousness about the need to properly respond to the HCV epidemic, assist advocates for HCV services in fostering the development of services, and assist programs that want to enhance services by informing them about "best practices."